Loading…
Karyopharm Therapeutics Inc. is projected to rise to $2.27 by 2027, a +15% move from its current price of $1.97. KPTI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.84 | $1.97 | $2.12 | +0.13% |
| Aug 6 | $1.79 | $1.98 | $2.18 | +0.27% |
| Aug 7 | $1.75 | $1.98 | $2.23 | +0.41% |
| Aug 8 | $1.72 | $1.98 | $2.28 | +0.54% |
| Aug 9 | $1.70 | $1.98 | $2.32 | +0.68% |
| Aug 10 | $1.67 | $1.99 | $2.36 | +0.81% |
| Aug 11 | $1.65 | $1.99 | $2.39 | +0.95% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.65 | $1.99 | $2.39 | +0.95% |
| Week 2 | $1.54 | $2.01 | $2.61 | +1.90% |
| Week 3 | $1.47 | $2.03 | $2.80 | +2.87% |
| Week 4 | $1.41 | $2.05 | $2.97 | +3.84% |
| Week 5 | $1.36 | $2.07 | $3.13 | +4.83% |
| Week 6 | $1.32 | $2.08 | $3.29 | +5.82% |
| Week 7 | $1.29 | $2.10 | $3.44 | +6.82% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company that discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreements with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma.
Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Karyopharm Therapeutics Inc. (KPTI) is a healthcare stock with a current price of $1.92 and a market cap of $43.51M, ranking 4562.
The price outlook shows a path of gradual upside across the coming years, with the long-range forecast projecting rising average prices and meaningful ROIs in the years beyond 2026.
From 2026 to 2030, the forecast lists the annualized average prices as: 2026 $1.92, 2027 $2.20, 2028 $2.12, 2029 $2.05, 2030 $2.19.
Beyond 2030, the forecast turns more bullish, with 2031-2050 showing higher averages and sizable ROIs, including 2031 avg $2.48 (ROI 28.9%), 2032 avg $3.04 (ROI 58.4%), 2033 avg $3.76 (ROI 95.7%), 2040 avg $4.98 (ROI 159.3%), and 2050 avg $8.12 (ROI 322.7%).
A major floor 2.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.5% away) — a key level to hold.
The nearest ceiling, 441.6% above — a clean break opens room to run.
A major ceiling 589.7% above — clearing it would confirm fresh momentum.
Key KPTI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KPTI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.99 | Sell | $5.39 | Sell |
| MA 10 | $6.70 | Sell | $6.53 | Sell |
| MA 20 | $8.32 | Sell | $7.60 | Sell |
| MA 50 | $8.83 | Sell | $8.38 | Sell |
| MA 100 | $8.36 | Sell | $8.32 | Sell |
| MA 200 | $7.63 | Sell | $7.96 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 15.96 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -263.46 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.52 | Sell |
| ROC (12) | -79.85 | Sell |
| Bollinger %B (20,2) | -0.30 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.83 | Sell |
| Awesome (5,34) | -2.81 | Sell |
| Ultimate (7,14,28) | 10.93 | Buy |
| Momentum (10) | -7.59 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 5.35 | Sell |
| ADX (14) | 25.23 | Sell |
| ATR (14) | 0.68 | Info |
The 30-day technical picture is NEUTRAL.
RSI14 is 20, indicating oversold conditions relative to recent activity. The 50-day simple moving average is $8.83 and the 200-day simple moving average is $7.63, framing a backdrop of weak price momentum relative to longer-term trends.
The stock sits near a support level at $1.92 and faces resistance at $10.67. The 30-day price range runs from a low of $1.21 to a high of $3.05.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.92 | $1.97 | $3.18 | 0% | Neutral | |
| $1.65 | $2.27 | $3.37 | +15% | Neutral | |
| $1.49 | $2.18 | $3.45 | +11% | Neutral | |
| $1.36 | $2.08 | $3.47 | +6% | Neutral | |
| $1.40 | $2.25 | $3.90 | +14% | Neutral | |
| $1.51 | $2.54 | $4.55 | +29% | Bullish | |
| $1.76 | $3.10 | $5.74 | +58% | Bullish | |
| $2.11 | $3.86 | $7.34 | +96% | Bullish | |
| $1.94 | $3.69 | $7.19 | +87% | Bullish | |
| $1.72 | $3.40 | $6.79 | +73% | Bullish | |
| $2.30 | $5.10 | $11.19 | +159% | Bullish | |
| $3.73 | $8.28 | $19.05 | +320% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.92 | $1.97 | $2.51 | +0.00% |
| September 2026 | $1.81 | $2.20 | $2.79 | +11.85% |
| October 2026 | $1.81 | $2.23 | $2.88 | +1.09% |
| November 2026 | $1.79 | $2.23 | $2.93 | -0.10% |
| December 2026 | $1.89 | $2.38 | $3.18 | +7.01% |
Click any year to see its month-by-month KPTI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Karyopharm Therapeutics Inc.'s 2026 outlook centres on $1.97, within a $1.92 to $3.18 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, KPTI could reach as high as $3.37, with a base case around $2.27 and support toward $1.65 — roughly +15% from $1.97. Price action looks broadly range-bound.
Expect KPTI to range from $1.49 to $3.45 through 2028. The $2.18 average target implies a +11% move from current prices. That is -4% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The KPTI price prediction for 2029 points to an average of $2.08 (low $1.36, high $3.47) — a potential gain of +6% on today's $1.97. Price action looks broadly range-bound.
In 2030, KPTI is projected to trade between $1.40 and $3.90, averaging $2.25 — a potential gain of +14% from today's $1.97. That is up +8% on the projected 2029 average. A consolidation phase looks the most probable path here.
Karyopharm Therapeutics Inc.'s 2031 outlook centres on $2.54, within a $1.51 to $4.55 range. That is up +13% on the projected 2030 average. That marks a +29% change versus current levels. Momentum favours further upside here.
By 2032, KPTI could reach as high as $5.74, with a base case around $3.10 and support toward $1.76 — roughly +58% from $1.97. Buyers look set to stay in control over this stretch.
Expect KPTI to range from $2.11 to $7.34 through 2033. The $3.86 average target implies a +96% move from current prices. That is up +24% on the projected 2032 average. Momentum favours further upside here.
The KPTI price prediction for 2034 points to an average of $3.69 (low $1.94, high $7.19) — a potential gain of +87% on today's $1.97. Buyers look set to stay in control over this stretch.
In 2035, KPTI is projected to trade between $1.72 and $6.79, averaging $3.40 — a potential gain of +73% from today's $1.97. That is -8% versus the projected 2034 average. Momentum favours further upside here.
Karyopharm Therapeutics Inc.'s 2040 outlook centres on $5.10, within a $2.30 to $11.19 range. That is up +50% on the projected 2035 average. That marks a +159% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, KPTI could reach as high as $19.05, with a base case around $8.28 and support toward $3.73 — roughly +320% from $1.97. Momentum favours further upside here.
Investing $1,000 in KPTI today (≈ 507.614213 KPTI) could be worth
$4,203.79
+$3,203.79 (+320%) by 2050 · US Dollar
Based on the average projected KPTI price of $8.28 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KPTIwould be worth at today's price.
$1,000 invested in KPTI on Jul 31, 2025 (≈ 262.467196 KPTI) would be worth
$517.06
-$482.94 (-48.3%) today · 0.52× · US Dollar
Based on a KPTI entry price of $3.81 vs. today's $1.97.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.41 | $265.86 | -73.4% |
| 1 month ago | $9.55 | $206.28 | -79.4% |
| 3 months ago | $8.77 | $224.63 | -77.5% |
| 6 months ago | $6.31 | $312.2 | -68.8% |
| 1 year ago | $3.81 | $517.06 | -48.3% |
| All time (5.0y) ago | $88.95 | $22.15 | -97.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KPTI forecast.
Our base-case forecast reaches $3.90 around 2040.
Implied market cap at $3.90: $88.39M
The multi-year forecast shows a bullish trajectory from the 2030s into the 2050s, with rising average prices and expanding ROIs.
In 2031 the average is projected at $2.48 with an ROI of 28.9%; in 2032 an average of $3.04 (58.4% ROI); and in 2033 an average of $3.76 (95.7% ROI).
The forecast continues to improve into 2040 and 2050, with 2040 an average of $4.98 (159.3% ROI) and 2050 an average of $8.12 (322.7% ROI). These are estimates, not guarantees, and depend on a range of uncertain factors; they reflect the modeled outlook under the given inputs.
Tap a question to reveal the answer.
Min $1.35, Avg $2.19, Max $3.78 with ROI 13.8%. (Forecasted values for 2030)
Forecasts show neutral for near term with a bullish shift from 2031 onward, including 2031 avg $2.48 and ROI 28.9%, 2050 avg $8.12 with ROI 322.7%.
Yes—the 2040 forecast max is $10.92, indicating the potential to exceed $10 by 2040.
Current price is $1.92 and market cap is $43.51M.
Min $3.65, Avg $8.12, Max $18.67 with ROI 322.7%; sentiment is BULLISH.
Karyopharm Therapeutics Inc. Community Discussion
0Share your Karyopharm Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.